May 24, 2017 / 10:44 AM / 3 months ago

BRIEF-Kamada Ltd presents updated data from phase 2 clinical trial of inhaled alpha-1-antitrypsin

May 24 (Reuters) - Kamada Ltd:

* Kamada Ltd presents updated data from phase 2 clinical trial of inhaled alpha-1-antitrypsin for treatment of alpha-1 antitrypsin deficiency

* Kamada - believe that the findings, as well as previously announced top-line data from this trial, support use of inhaled AAT for treatment of aatd

* Kamada Ltd - expect to have an approved investigational new drug application to conduct a pivotal phase 3 study prior to end of year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below